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pathways.5 NAFLD, according to epidemiological 
data, is a risk factor for cardiovascular events as 
well as risk factor of diabetic microangiopathy, 
including chronic kidney disease.5-8
Pentraxin 3 (PTX3) is an acute ‑phase reactant 
and an essential component of innate immuni‑
ty. PTX3 shares structural and functional homol‑
ogy with C ‑reactive protein and is a member of 
the long pentraxin superfamily, which are soluble 
proteins induced by various inflammatory stimu‑
li. PTX3 activates the complement system, binds 
microbial surfaces and apoptotic cells, and aids 
in their clearance.9 PTX3 is produced at the site 
of inflammation by macrophages, dendritic cells, 
neutrophils, fibroblasts, chondrocytes endothelial 
INTRODUCTION Nonalcoholic fatty liver disease 
(NAFLD) is one of the most common causes of 
chronic liver injury in numerous countries around 
the world. NAFLD is present in up to 50% to 80% 
of patients with type 2 diabetes (T2D). NAFLD is 
associated with insulin resistance, central obesi‑
ty, hypertension, and atherogenic dyslipidemia, 
including hypercholesterolemia, hypertriglycer‑
idemia, postprandial lipemia, low serum high‑
‑density lipoprotein cholesterol (HDL ‑C) concen‑
trations, and HDL dysfunction.1-4
It has been shown that the clinical burden 
of NAFLD is not confined only to liver ‑related 
morbidity and mortality. It is a multisystem dis‑
ease, affecting extrahepatic organs and regulatory 
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ABSTRACT
INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is common in patients with type 2 diabetes 
(T2D). Pentraxin 3 (PTX3), a marker of inflammation, is a cardiovascular risk factor.
OBJECTIVES We examined clinical and biochemical factors associated with serum PTX3 concentrations 
in patients with T2D with and without NAFLD.
PATIENTS AND METHODS Serum material was obtained from 116 patients with T2D (mean age, 59.1 
years), including 79 patients with NAFLD.
RESULTS Median (interquartile range) PTX3 level was 4.264 (2.293) ng/ml in patients with and 3.773 
(3.223) ng/ml in patients without NAFLD (P = 0.93). In the whole group, PTX3 level was associated 
with total cholesterol, low ‑density lipoprotein cholesterol (LDL ‑C), apolipoprotein (apo) B100, apo C3, 
triglyceride (TG) concentrations, and waist circumference after adjustment for age and gender. As 
indicated by partial regression coefficient b, increase of independent variable LDL ‑C by 1 mmol/l was 
associated with the rise of PTX3 by 1.2017 ng/ml, increase of apo B100 by 1 mg/dl with the rise of PTX3 
by 1.0051 ng/ml, and increase of apo C3 by 1 µg/dl with the rise of PTX3 by 1.0012 ng/ml. In patients 
with T2D with NAFLD, total cholesterol, LDL ‑C, TG, apo C3, and apo B100 were associated with PTX3. 
Associations of PTX3 with apolipoproteins were observed only in the NAFLD group.
CONCLUSIONS Reported associations of PTX3 level add new insight into possible mechanisms of its 
atherogenic actions.
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NAFLD including bright hepatic echoes, increased 
hepatorenal echogenicity, vascular blurring of  the 
portal or hepatic vein were evaluated.17,18
Written informed consent was obtained from 
each patient included in the study. The study 
protocol conforms to the ethical guidelines of 
the 1975 Declaration of Helsinki and was ap‑
proved by the Ethics Committee of Jagiello‑
nian University Medical College (decision no. 
122.6120.173.2015; date: June 26, 2015). 
Statistical analysis The t test and Mann–Whit‑
ney test were used for a comparison of selected 
variables between the groups of patients with and 
without NAFLD. Statistical analysis included cal‑
culations of means (SD) for normally distributed 
variables and medians (interquartile range [IQR]) 
for not normally distributed variables and calcu‑
lations of the Pearson and Spearman rank corre‑
lation coefficients. Regression analysis for each 
variable, with PTX3 as a dependent variable, was 
performed after logarithmic transformation of 
PTX3 because of a large skewness of its distri‑
bution. The independent variables in regression 
analysis were: body mass index (BMI), waist / hip 
ratio (WHR), serum concentration of total cho‑
lesterol (TC), TG, HDL ‑C, low ‑density lipopro‑
tein cholesterol (LDL ‑C), glucose, creatinine, ac‑
tivity of alanine and asparagine aminotransfer‑
ases, γ ‑glutamyltranspeptidase. The analysis ad‑
justed for age and sex was performed in the whole 
study group and in the subgroups that were di‑
vided according to NAFLD.
RESULTS We examined 116 patients with T2D, 
and 79 of them had NAFLD. In the whole group, 
86.2% of patients had arterial hypertension, 
68.7%, hyperlipidemia, and 36.2%, coronary heart 
disease. In the NAFLD group, 91.1% had arterial 
hypertension, 82.2%, hyperlipidemia, and 39.2%, 
coronary heart disease. Clinical characteristics 
and laboratory data for the whole study group 
and subgroups (with and without NAFLD) are 
shown in TABLE 1. Patients with T2D and NAFLD 
were younger (P = 0.01), had lower HDL ‑C con‑
centrations (P = 0.02), higher values of transam‑
inases and γ ‑glutamyltranspeptidase (as expect‑
ed, although still within normal limits), and high‑
er waist circumference (P <0.05). We did not ob‑
serve differences in serum apolipoprotein con‑
centrations or glycemic control between patients 
with and without NAFLD (TABLE 1).
Concentrations of PTX3 in the whole group of 
patients correlated positively with serum concen‑
trations of lipids and apolipoprotein: TC (r = 0.46; 
P <0.001), LDL ‑C (r = 0.36; P <0.001), TG (r = 0.42; 
P <0.001), apo C3 (r = 0.29; P = 0.002), apo B100 
(r = 0.31; P <0.001), glucose (r = 0.21; P = 0.04) lev‑
els, and BMI (r = 0.20; P = 0.03) (TABLE 2). Interest‑
ingly, in the NAFLD group, serum PTX3 correlated 
with TC (r = 0.47; P <0.001) and LDL ‑C (r = 0.39; 
P = 0.001), TG (r = 0.39; P <0.001), apo C3 (r = 
0.43; P <0.001), apo B100 (r = 0.34; P = 0.002), 
while in patients with T2D and without NAFLD it 
cells and adipocytes, and smooth muscle cells.9 
Its production is induced by interleukin 1, tu‑
mor necrosis factor α, oxidized low ‑density lipo‑
protein, and microbial moieties.9,10 PTX3 inter‑
acts with ancestral domains conserved in innate 
immunity, hemostasis, and extracellular matrix 
and exerts functions related to antimicrobial re‑
sistance and tissue repair.11
PTX3, a  marker of inflammation, is inde‑
pendently associated with the risk of vascular 
events.12-14 There are data indicating that PTX3 
also has anti ‑inflammatory and cardioprotective 
properties.15 Plasma PTX3 level is, according to 
some data, a marker for nonalcoholic steatohep‑
atitis and severity of liver fibrosis.16
In this study we aimed to determine factors as‑
sociated with serum PTX3 concentrations in pa‑
tients with T2D with and without NAFLD.
PATIENTS AND METHODS A total of 116 consec‑
utive patients (mean age, 59.1 years) with T2D 
from the outpatient diabetic clinic were included 
in the study. T2D was diagnosed at least 2 years 
before inclusion to the study. Patients with acute 
or chronic inflammatory processes and devastat‑
ing diseases were excluded. Medical history was 
taken from all patients and they were asked about 
alcohol consumption. Persons who defined them‑
selves as alcohol drinkers or those who drank 
more than 30 g of ethanol daily (or equivalent) 
for men and 20 g for women were excluded from 
the study. Patients with autoimmunological, met‑
abolic, or viral liver disease were excluded from 
participation in the study. All patients answered 
a standardized questionnaire, and in each patient 
the following analyses were performed: anthropo‑
metric measurements, fasting serum lipids, apoli‑
poproteins (apos), liver enzymes, creatinine, glu‑
cose, and glycated hemoglobin A1c (HbA1c). Waist 
circumference was measured midway between 
the lowest lateral border of the ribs and the up‑
permost lateral iliac crest. Body weight was mea‑
sured in light clothing and with shoes on.
Fasting serum lipids concentrations were de‑
termined by enzymatic methods using Roche re‑
agents (Roche Diagnostics, Mannheim, Germa‑
ny) and HbA1c, by high ‑pressure liquid chroma‑
tography. Cytokeratin 18 fragment – a marker of 
NAFLD – PTX3, as well as apo C3, B100, and B48 
were determined by enzyme‑linked immunosor‑
bent assays (cytokeratin 18, Peviva AB, Bromma, 
Sweden; PTX3, Cloud‑Clone Corp., Houston, Tex‑
as, United States; apo C3, Abnova Co., Taipei City, 
Taiwan; apo B100, Cloud‑Clone Corp.; and apo 
B48, Shibayagi Co., Gunma, Japan). Apo A1 was 
determined by the immunoturbidimetric meth‑
od (Aptec Diagnostics NV, Sint‑Niklaas, Belgium). 
NAFLD was diagnosed by ultrasonography, which 
has a sensitivity and specificity up to 95% for 
the detection of liver steatosis. Ultrasonograph‑
ic measurements were performed by 2 experi‑
enced radiologists who were blinded to the clini‑
cal presentations and laboratory finding of the pa‑
tients. The characteristic sonographic findings for 
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associated with PTX3. An increase by 1 mmol/l 
of TC, LDL ‑C, and TG was related with an in‑
crease of PTX3 by 1.1822 ng/ml, 1.1779 ng/ml, 
and 1.1293 ng/ml respectively. An increase of apo 
C3 by 1 µg/dl and apo B100 by 1 mg/dl was relat‑
ed with an increase of PTX3 by 1.0014 ng/ml and 
1.0051 ng/ml, respectively.
In patients without NAFLD, associations be‑
tween PTX3 and TC and LDL ‑C were found, and 
a positive association with waist circumference 
was observed. An increase of waist circumfer‑
ence by 1 cm in these patients was associated with 
an increase of PTX3 by 1.0144 ng/ml.
DISCUSSION The results of this study indicate 
that PTX3, an inflammation marker, in patients 
with T2D is associated with TC, LDL ‑C, apo B100, 
apo C3, TG, glucose levels and BMI in the whole 
study group of patients with T2D.
We did not observe differences in concentra‑
tions of PTX ‑3 between patients with and without 
NAFLD, as observed in patients with and with‑
out liver fibrosis16; however, we did not perform 
liver biopsy. In our study, patients with T2D and 
was correlated with TC (r = 0.46; P = 0.01), TG (r = 
0.50; P = 0.004), waist circumference (r = 0.38; 
P = 0.02), and BMI (r = 0.42; P = 0.009) (TABLE 2).
TABLE 3 presents partial regression coefficients 
and partial correlation coefficients between se‑
lected variables and logPTX3, after adjustment 
for age and sex in the whole study group. PTX3 
level was associated with the concentrations of 
TC, LDL ‑C, apo B100, apo C3, and TG and waist 
circumference. As indicated by partial regression 
coefficient b, change of independent variable LDL‑
‑C was associated with the greatest change of 
PTX3, while smaller associations were observed 
also with TC and TG. An increase of TC, LDL ‑C, 
and TG by 1 mmol/l was associated with an in‑
crease of PTX3 by 1.1959 ng/ml, 1.2017 ng/ml, 
and 1.1405 ng/ml respectively. An increase of apo 
B100 by 1 mg/dl was associated with an increase 
of PTX3 by 1.0051 ng/ml, and of apo C3 by 1 µg/dl 
with PTX3 by 1.0012 ng/ml.
Similar results were observed in patients with 
T2D and NAFLD as in the whole group (TABLE 3). 
Total cholesterol, LDL ‑C, TG, apo C3, and apo 
B100, after adjustment for age and sex, were 
TABLE 1 Characteristic of selected variables in patients with type 2 diabetes according to nonalcoholic fatty liver disease
Parameter Total (n = 116) Nonalcoholic fatty liver disease P value
Present (n = 79) Absent (n = 37)
n X/Mea SD/IQR n X/Mea SD/IQR n X/Mea SD/IQR
Age, y 116 59.1 11.07 79 57.3 10.6 37 62.9 11.21 0.01
Diabetes duration, ya 114 9 10 78 8 9 36 9 11 0.44
HbA1c, % 87 8.6 2.3 62 8.54 2.19 25 8.8 2.64 0.64
TC, mmol/l 106 4.72 1.36 76 4.59 1.25 30 5.03 1.58 0.14
TG, mmol/la 106 1.8 1 76 1.9 1.2 30 1.6 1.0 0.19
HDL ‑C mmol/l 106 1.14 0.3 76 1.09 0.25 30 1.26 0.36 0.02
LDL ‑C, mmol/l 98 2.6 1.16 69 2.49 1.04 29 2.89 1.38 0.12
AST, U/la 109 25 15 76 25.5 20 33 20 10 0.01
ALT, U/la 110 28.5 24 77 31 29 33 22 14 0.001
GGTP, U/la 106 29 23 74 32 41 32 24 12.5 0.001
Glucose, mmol/la 91 7 3 59 7.2 3.2 32 6.9 3.2 0.53
Creatinine, μmol/la 108 76 22 76 76.5 19 32 74.5 25 0.79
Uric acid, μmol/l 103 346.8 94.95 69 353.4 98.47 34 333.3 87.22 0.31
Bilirubin, mg/dl 95 11.44 4.82 67 11.78 4.89 28 10.63 4.65 0.29
Apo C3 μg/mla 115 223.8 122.9 79 243.7 123.6 36 208.2 131 0.06
Waist circumference, cm 113 109.1 13.1 78 110.8 11.97 35 105.3 14.82 0.04
WHR 112 0.99 0.0756 77 0.998 0.0761 35 0.973 0.0727 0.11
BMI, kg/m2 116 32.74 5.788 79 33.44 5.12 37 31.23 6.842 0.09
CK ‑18, U/la 116 197.1 189.2 79 206.4 201.4 37 181.9 103.9 0.08
PTX3, ng/mla 116 4.11 2.44 79 4.26 2.29 37 3.77 3.22 0.93
Apo B48, ng/mla 115 3766 3234 78 3459.5 3105 37 4529 3959 0.3
Apo B100, mg/dl 116 88.84 25.79 79 87.8 26.93 37 91.06 23.35 0.53
Apo A1, mg/dl 116 141.56 28.77 79 140.29 28.53 37 144.26 29.49 0.5
a Nonnormally distributed variable – median (Me) and interquartile range (IQR) are presented. Comparison of distributions (Me), Mann–Whitney 
test; in other cases comparisons of the means were made using t test.
Abbreviations: ALT, alanine transaminase; apo, apolipoprotein; AST, aspartate transaminase; BMI, body mass index; CK ‑18, cytokeratin 18 fragment; 
GGTP, γ ‑glutamyltranspeptidase; HbA1c, glycated hemoglobin A1c; HDL ‑C, high ‑density lipoprotein cholesterol; LDL ‑C, low ‑density lipoprotein 
cholesterol; PTX3, pentraxin 3; TC, total cholesterol; TG, triglycerides; WHR, waist ‑to ‑hip ratio; X, mean
POLISH ARCHIVES OF INTERNAL MEDICINE 2019; 129 (7-8)502
with different stages of CAD. There are data indi‑
cating that exposure of arterial vascular smooth 
muscle cells to modified LDL in vitro markedly in‑
creased PTX3 expression.23 However, contrary to 
our findings, inverse correlations between LDL ‑C 
and PTX3 were observed in women with gesta‑
tional diabetes24 and in insulin ‑resistant patients 
from the Health 2000 Survey.13 In this study in 
insulin ‑resistant patients, PTX3 concentration 
variations were attributed to variations in LDL‑
‑C. Also negative association between PTX3 and 
LDL ‑C and apo B100, marker of all atherogenic 
lipoproteins, was observed by Morishita et al25 in 
163 Japanese patients with stable angina pectoris.
Data from several studies indicate that there 
is an association between apo B and the presence 
of NAFLD. In a study by Wang et al,26 elevated se‑
rum apo B levels independently predicted an in‑
creased risk for incident NAFLD in Chinese pop‑
ulation.26 The association of NAFLD with apo 
B dyslipoproteinemias was confirmed by Nass 
et al27 in the Lifelines Cohort Study. Associations 
between apo B and PTX3, found in our patients 
with NAFLD are in line with these data.
Positive association between PTX3 and apo C3 
is of importance, especially in the light of its func‑
tion in lipid metabolism and in increasing athero‑
sclerosis risk. Apo C3 is now recognized as the key 
NAFLD were younger and had lower HDL ‑C and 
higher waist circumference than patients without 
fatty liver disease. Lallukka et al19 found that the 
presence of NAFLD predicts the risk of T2D inde‑
pendently of age, which might explain the young‑
er age of patients with NAFLD in our study as they 
might have had T2D earlier than patients with‑
out NAFLD.19 Lower HDL ‑C concentrations in pa‑
tients with NAFLD were also observed by some 
authors, for example DeFilippis et al,20 but not 
by others, for example Bril et al.21 Patients with 
NAFLD had higher activity of liver enzymes (as 
expected, although still within normal limits), 
than patients without the disease. Interestingly, 
we did not find any differences in other lipid or 
apolipoprotein concentrations or glucose control 
between groups assessed by HbA1c level.
Serum PTX3 levels correlated with TC and 
TG levels in all patients regardless of the pres‑
ence of NAFLD. In the whole study group and in 
patients with NAFLD, the correlations between 
PTX3 and strong cardiovascular lipid risk factors, 
that is, LDL ‑C, apo B100, and apo C3, were ob‑
served. Apo B100 is a marker of atherogenic lipo‑
proteins of hepatic origin – very LDL, LDL, and 
small dense LDL – and a strong cardiovascular risk 
factor. Positive associations between PTX3 and 
LDL ‑C were observed by Hydzik et al22 in patients 
TABLE 2 Spearman correlation coefficients of selected variables and serum pentraxin 3 concentrations in patients with type 2 diabetes according to 
nonalcoholic fatty liver disease
Parameter Total (n = 116) Nonalcoholic fatty liver disease
Present (n = 79) Absent (n = 37)
n rS P value n rS P value n rS P value
Age, y 116  – 0.05 0.629 79  – 0.09 0.44 37 0.01 0.93
Diabetes duration, y 114 0.01 0.932 78 0.03 0.77 36  – 0.04 0.81
HbA1c, % 87 0.12 0.285 62 0.17 0.17 25  – 0.01 0.97
TC, mmol/l 106 0.46 <0.001 76 0.47 <0.001 30 0.46 0.01
TG, mmol/l 106 0.42 <0.001 76 0.39 <0.001 30 0.50 0.004
HDL ‑C mmol/l 106  – 0.09 0.34 76  – 0.12 0.3 30  – 0.07 0.7
LDL ‑C, mmol/l 98 0.36 <0.001 69 0.39 0.001 29 0.34 0.07
AST, U/l 109 0.00 0.96 76 0.04 0.71 33  – 0.14 0.42
ALT, U/l 110  – 0.09 0.34 77  – 0.10 0.36 33  – 0.17 0.35
GGTP, U/l 106  – 0.01 0.94 74  – 0.01 0.95 32  – 0.03 0.87
Glucose, mmol/la 91 0.21 0.04 59 0.24 0.07 32 0.18 0.33
Creatinine, μmol/la 108 0.06 0.52 76 0.07 0.55 32 0.08 0.67
Uric acid, μmol/l 103 0.10 0.29 69 0.11 0.37 34 0.08 0.66
Bilirubin, mg/dl 95  – 0.19 0.05 67  – 0.17 0.16 28  – 0.27 0.16
Apo C3, μg/mla 115 0.29 0.002 79 0.43 <0.001 36  – 0.04 0.81
Waist circumference, cm 113 0.16 0.08 78 0.07 0.54 35 0.38 0.02
WHR 112 0.04 0.6394 77 0.03 0.80 35 0.01 0.93
BMI, kg/m2 116 0.20 0.03 79 0.08 0.48 37 0.42 0.009
CK ‑18, U/l 116 0.05 0.592 79 0.04 0.7 37 0.08 0.65
Apo B48, ng/ml 115 0.16 0.086 78 0.16 0.17 37 0.22 0.18
Apo B100, mg/dl 116 0.31 <0.001 79 0.34 0.0023 37 0.23 0.16
Apo A1, mg/dl 116 0.16 0.083 79 0.07 0.5281 37 0.29 0.07
Abbreviations: see TABLE 1
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insulin, systolic blood pressure, C ‑reactive protein, 
and carotid intima media thickness.37 The discrep‑
ancies in association between PTX3 and obesi‑
ty indices could be due to differences in body fat 
mass and fat tissue distribution.
In our group, we did not observe any associ‑
ations between PTX3 and diabetes control, as‑
sessed by HbA1c levels, in line with data present‑
ed by Takashi et al.38
Recent observations have led some authors to 
postulate that an increase in PTX3 levels should 
be regarded as an attempt to counterbalance 
the overactivation of the proinflammatory cas‑
cade induced by interleukin 1, tumor necrosis 
factor α, oxidized low ‑density lipoprotein, and 
microbial moieties, rather than as a harmful re‑
sponse.39-41 PTX3 provides an anti ‑inflammatory 
property to downregulate the production of pro‑
inflammatory cytokines, playing multiple roles in 
the development of atherothrombotic plaque.39-41 
Based on data from the available literature, it 
seems that PTX3 acts as a crossroad between pro‑ 
and anti ‑inflammatory pathways as an modulato‑
ry molecule, influencing inflammatory response 
and tissue remodeling.12
The associations between PTX3 and apo B and 
apo C3 in patients with T2D are of value in un‑
derstanding the role of inflammation in NAFLD 
and vascular disease. The SUMMIT VIP (Surrogate 
Markers for Micro‑ and Macrovascular Hard End‑
points for Innovative Diabetes Tools – Vascular 
inhibitor of lipoprotein lipase and hepatic lipase 
and it also enhances synthesis and secretion of 
very LDL from the liver, thus leading to severe 
hypertriglyceridemia. Apo C3 is an atherogenic 
protein found on HDL, very LDL, and LDL and 
confers increased cardiovascular risk.28 There are 
also data from genetic gain ‑of ‑function apo C3 
mutations and clinical studies with apo C3 inhi‑
bition indicating that this apo is associated with 
incident cardiovascular disease.29,30 Besides its 
effects on lipid and lipoprotein metabolism, apo 
C3 is directly involved in stimulation of vascular 
inflammatory processes. There are data indicat‑
ing that apo C3 directly provokes proinflamma‑
tory responses in vascular cells, including mono‑
cytes and endothelial cells.31,32
The findings on association between circulat‑
ing levels of PTX3 and measures of adiposity are 
inconsistent: some studies have found positive, 
whereas other have demonstrated inverse asso‑
ciations.33-35 In our patients with T2D without 
NAFLD, positive association between PTX3 and 
waist circumference and BMI was found, while, in‑
terestingly, in patients with NAFLD such associa‑
tion did not occur. Alberti et al36 found that PTX3 
expression tended to be higher in obese patients 
than in those with normal weight only in viscer‑
al adipose tissue and correlated with LDL / HDL 
ratio in the multivariate analysis.36 In the MESA 
(Multi ‑Ethnic Study of Atherosclerosis) study, 
PTX3 was positively associated with age, obesity, 
TABLE 3 Partial regression coefficients and partial correlation coefficients between selected variables and logPTX3 in the whole study group with 
type 2 diabetes and according to presence of nonalcoholic fatty liver disease, after adjustment for age and sex
Parameter Total (n = 116) Nonalcoholic fatty liver disease
Present (n = 79) Absent (n = 37)
b* r R2 P value b* r R2 P value b* r R2 P value
TC, mmol/l 0.4982 0.07 0.24 <0.001 0.4889 0.47 0.07 <0.001 0.4790 0.49 0.13 0.0087
LDL ‑C, mmol/l 0.4312 0.43 0.08 <0.001 0.3968 0.38 0.09 0.0014 0.4527 0.47 0.08 0.0136
HDL ‑C, mmol/l  – 0.0686  – 0.07 0.06 0.4920  – 0.1121  – 0.11 0.05 0.3510  – 0.0722  – 0.08 0.02 0.6954
TG, mmol/l 0.3395 0.34 0.05 <0.001 0.3852 0.38 0.06 <0.001 0.2662 0.28 0.05 0.1472
HbA1c, % 0.0831 0.08 0.03 0.4483 0.1940 0.19 0.03 0.1428  – 0.0419  – 0.05 0.04 0.8320
Glucose, mmol/l 0.1518 0.16 0.01 0.1450 0.1796 0.18 0.07 0.1931 0.1725 0.18 0.01 0.3296
AST, U/l 0.0131 0.01 0.11 0.8976 0.0249 0.02 0.11 0.8422  – 0.0114  – 0.02 0.11 0.9383
ALT, U/l  – 0.0845  – 0.08 0.17 0.4184  – 0.1046  – 0.10 0.15 0.4087  – 0.0390  – 0.04 0.21 0.8398
GGTP, U/l 0.0450 0.04 0.10 0.6616 0.0920 0.09 0.07 0.4577  – 0.0109  – 0.01 0.14 0.9541
Creatinine, μmol/l 0.1713 0.16 0.15 0.1001 0.2089 0.20 0.12 0.0922 0.1605 0.14 0.34 0.4604
WHR 0.1236 0.10 0.37 0.3001 0.0559 0.04 0.49 0.7343 0.1083 0.11 0.20 0.5594
BMI, kg/m2 0.1487 0.15 0.04 0.1143 0.0856 0.08 0.04 0.4662 0.2470 0.26 0.06 0.1306
Apo C3, μg/ml 0.2702 0.27 0.06 0.0041 0.4303 0.42 0.04 <0.001 0.0749 0.08 0.15 0.6743
Waist 
circumference, cm
0.2019 0.20 0.04 0.0335 0.0807 0.08 0.06 0.4992 0.3562 0.37 0.09 0.0342
CK ‑18, U/l 0.0584 0.06 0.10 0.5499 0.0856 0.08 0.09 0.4785  – 0.0362  – 0.04 0.18 0.8394
Apo B48, ng/ml 0.1756 0.18 0.02 0.0597 0.1848 0.18 0.03 0.1148 0.1149 0.12 0.02 0.4804
Apo B100, mg/dl 0.2678 0.27 0.01 0.0035 0.3261 0.32 0.05 0.0046 0.1873 0.20 0.01 0.2436
Apo A1, mg/dl 0.1339 0.14 0.001 0.1475 0.0988 0.10 0.004 0.3915 0.1677 0.18 0.004 0.2958
b* – standardized partial regression coefficient;   r – partial correlation coefficient;   R2 – partial determination coefficient
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Imaging Prediction) study demonstrated that 
markers of inflammation, including PTX3, as well 
as markers of endothelial stress reflect cardiovas‑
cular risk in patients with T2D with manifest mac‑
roangiopathy, whereas conventional risk factors 
were not associated with cardiovascular events 
in these patients.42
Treatment of lipid disorders in patients with 
NAFLD could be of value in reducing cardiovas‑
cular risk as well as preventing liver disease pro‑
gression, as suggested by expert panels.43,44
The limitations of this study include a rel‑
atively small number of examined patients in 
the group without NAFLD and lack of confirma‑
tion of NAFLD diagnosis by liver biopsy.
In conclusion, PTX3, a marker of cardiovascu‑
lar risk and inflammation in patients with T2D 
is associated with TC, TG, LDL ‑C, apo B, and apo 
C3. Associations with LDL ‑C and apos persist only 
in NAFLD patients. The results of our study could 
be of value in understanding the parameters in‑
fluencing PTX3 in patients with T2D and, there‑
fore, in personalized treatment.
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